.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01E_SulfonamidesAndTrimethoprim.J01EA01_Trimethoprim.Trimethoprim_1

Information

Trimethoprim is an antibiotic that inhibits bacterial dihydrofolate reductase, interfering with folic acid synthesis required for bacterial DNA replication. It is commonly used, often in combination with sulfamethoxazole, for the treatment of urinary tract infections and a variety of other bacterial infections. Trimethoprim is a widely approved and routinely prescribed antimicrobial agent.

Pharmacokinetics

Pharmacokinetic parameters after intravenous administration in healthy adults.

References

1. Sullins, AK, & Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatric drugs 15(2) 93–117. DOI:10.1007/s40272-013-0017-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23529866

2. Ekstrand, C, et al., & Bröjer, J (2022). The disposition of trimethoprim and sulfadiazine in neonatal foals after intravenous administration. Veterinary medicine and science 8(3) 1065–1071. DOI:10.1002/vms3.763 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35152563

3. Kim, P, et al., & Garofolo, PM (2024). Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. The Lancet. Infectious diseases 24(12) 1319–1332. DOI:10.1016/S1473-3099(24)00424-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39134085

Revisions

• 06/2025 initial generated model